For patients with HFPEF and other underlying comorbidities, such as diabetes or coronary artery disease, treatment with an ACE inhibitor is nonetheless beneficial. The theoretical benefits of ACE ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Following these results, the company has submitted tirzepatide for HFpEF and obesity treatment to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with plans to ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

Novo Nordisk recently pulled its FDA application for semaglutide as a HFpEF treatment in order to compile additional follow-up data, and has said it expects to refile early in 2025. Data on hard ...

HS-135 is under clinical development by 35Pharma and currently in Phase I for Diastolic Heart Failure (HFpEF).

Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic ...

SRD-002 is under clinical development by Sardocor and currently in Phase II for Diastolic Heart Failure (HFpEF).

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF ...

Our focus is on HFrEF including familal, dilated cardiomyopathy, HFpEF including amyloid cardiomyopathy ... more efficient, diagnosis, and treatment. Our focus is on improving the procedures and ...